Stopping weight-loss jabs raises heart and mental health risks
Summarised from 2 outlets · Updated 11 Nov, 15:28 · Archive
Stopping GLP-1 weight-loss drugs may double the risk of heart attack or stroke, a study finds.
A study published in The Lancet Regional Health analysed medical records of over 80,000 people with type 2 diabetes in Italy over ten years. Around 60 per cent of patients stopped taking glucagon-like peptide-1 (GLP-1) receptor agonists during the study period.
Researchers at the University of Campania found that those who discontinued treatment faced roughly double the risk of heart attack or stroke compared with those who continued. Their risk of dying from any cause was nearly five times higher. Crucially, patients who stopped treatment regained relatively little weight and showed only small differences in blood sugar control, suggesting the drugs may protect the heart through mechanisms beyond weight loss.
Meanwhile, the New York Post reports that case reports published in The Primary Care Companion CNS Disorders document psychiatric effects after stopping GLP-1 drugs. One case involved a 61-year-old man who stopped tirzepatide in August 2025 due to nausea. Two months later he was hospitalised with confusion, erratic behaviour, paranoia and hallucinations, eventually requiring electroconvulsive therapy. Doctors ruled out other causes through testing.

How it is being reported
- Some people are having hallucinations and other psychotic symptoms after stopping GLP-1 drugsStop taking GLP-1s, and the weight will likely to come back fast — and new reports warn your mental health can suffer too.New York Post · 11 Nov, 15:11
- Stopping weight-loss jabs could DOUBLE your risk of a heart attack or stroke - and make you five times more likely to die... even if you keep the weight off, experts discoverDiabetes patients who stop taking GLP-1s may face double the risk of heart attack, stroke or early death compared with those who stay on the drugs, a large study has found.Daily Mail · 9 Nov, 23:32
In this story: University of Campania · Italy · Ozempic
This summary was written by AI from the headlines and standfirsts above, and states as fact only what at least two outlets report. How we use AI · Report a problem · Corrections log
Comments (0)